Dystonia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Dystonia - Pipeline Review, H1 2016', provides an overview of the Dystonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dystonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dystonia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Dystonia - The report reviews pipeline therapeutics for Dystonia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dystonia therapeutics and enlists all their major and minor projects - The report assesses Dystonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dystonia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dystonia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dystonia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Dystonia Overview 6 Therapeutics Development 7 Pipeline Products for Dystonia - Overview 7 Pipeline Products for Dystonia - Comparative Analysis 8 Dystonia - Therapeutics under Development by Companies 9 Dystonia - Therapeutics under Investigation by Universities/Institutes 11 Dystonia - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Dystonia - Products under Development by Companies 15 Dystonia - Products under Investigation by Universities/Institutes 16 Dystonia - Companies Involved in Therapeutics Development 17 Addex Therapeutics Ltd 17 Advicenne Pharma 18 EpiVax, Inc. 19 Ipsen S.A. 20 Revance Therapeutics, Inc. 21 Dystonia - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 abobotulinumtoxin A - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 abobotulinumtoxin A next generation - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 dipraglurant ER - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 onabotulinumtoxin A - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 RT-002 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 tetrabenazine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Dystonia - Recent Pipeline Updates 39 Dystonia - Dormant Projects 43 Dystonia - Product Development Milestones 44 Featured News & Press Releases 44 Mar 05, 2016: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology 44 Oct 29, 2015: Revance Reports Positive 6-Month Duration in BELMONT Study 45 Sep 29, 2015: Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia 47 Feb 05, 2014: Ipsen announces clinical results of Dysport Next Generation and its intent to file the first ready-to-use liquid toxin A in Europe and ROW 47 Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved Botox 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Number of Products under Development for Dystonia, H1 2016 7 Number of Products under Development for Dystonia - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Dystonia - Pipeline by Addex Therapeutics Ltd, H1 2016 17 Dystonia - Pipeline by Advicenne Pharma, H1 2016 18 Dystonia - Pipeline by EpiVax, Inc., H1 2016 19 Dystonia - Pipeline by Ipsen S.A., H1 2016 20 Dystonia - Pipeline by Revance Therapeutics, Inc., H1 2016 21 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Stage and Target, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 26 Number of Products by Stage and Route of Administration, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 30 Dystonia Therapeutics - Recent Pipeline Updates, H1 2016 39 Dystonia - Dormant Projects, H1 2016 43
List of Figures
Number of Products under Development for Dystonia, H1 2016 7 Number of Products under Development for Dystonia - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Targets, H1 2016 23 Number of Products by Stage and Targets, H1 2016 23 Number of Products by Mechanism of Actions, H1 2016 25 Number of Products by Stage and Mechanism of Actions, H1 2016 25 Number of Products by Routes of Administration, H1 2016 27 Number of Products by Stage and Routes of Administration, H1 2016 27 Number of Products by Molecule Types, H1 2016 29 Number of Products by Stage and Molecule Types, H1 2016 29
Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.Read More...
Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiencyRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.